Stocks and Investing Stocks and Investing
Wed, September 4, 2024

Biren Amin Initiated (BBIO) at Buy and Held Target at $46 on, Sep 4th, 2024


Published on 2024-10-28 14:02:00 - WOPRAI, Biren Amin
  Print publication without navigation


Biren Amin of Piper Sandler, Initiated "BridgeBio Pharma, Inc." (BBIO) at Buy and Held Target at $46 on, Sep 4th, 2024.

Biren has made no other calls on BBIO in the last 4 months.



There are 6 other peers that have a rating on BBIO. Out of the 6 peers that are also analyzing BBIO, 0 agree with Biren's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Biren


  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $43 on, Tuesday, September 3rd, 2024
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $43 on, Wednesday, August 7th, 2024
  • Cory Kasimov of "Evercore ISI Group" Maintained at Buy with Decreased Target to $45 on, Wednesday, August 7th, 2024
  • Josh Schimmer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $70 on, Monday, July 1st, 2024
  • Geoff Meacham of "B of A Securities" Maintained at Strong Buy with Decreased Target to $42 on, Tuesday, June 25th, 2024
  • Eliana Merle of "UBS" Maintained at Strong Buy with Decreased Target to $47 on, Tuesday, May 28th, 2024
Contributing Sources